TY - JOUR
T1 - Romidepsin for the treatment of peripheral t-cell lymphoma
AU - Iyer, Swaminathan P.
AU - Foss, Francine F.
N1 - Publisher Copyright:
© Alpha Med Press 2015.
PY - 2015/6/22
Y1 - 2015/6/22
N2 - Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert hematopathologists improves accuracy of subtyping, and referral to academic or specialty centers is recommended. Many patients, however, will receive treatment in the community, and knowledge of approved agents is key to optimizing therapeutic approaches for all patients. There is no current standard ofcare for patients with PTCL and no approved therapies for first-line treatment. Although many patients initially respond to induction chemotherapy, responses are often brief, and many patients relapse or become treatment refractory. For patients with relapsed or refractory PTCL, achievement of durable responses is challenging, and there are few treatment options. Romidepsin is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received one prior systemic therapy or more and patients with PTCL who have received one prior therapy or more. Approval of romidepsin for PTCL was based on a pivotal phase II study of patients with relapsed or refractory PTCL (n 5 131) that demonstrated an objective response rate of 25% including 15% with complete response; responses lasted a median of.2 years. Long-term responses to romidepsin were achieved in patients regardless of baseline characteristics, including subtype, heavy pretreatment, response to prior therapy, or advanced disease. Common adverse events included hematologic abnormalities, gastrointestinal or asthenic conditions, and infections; romidepsin was not correlated with clinically meaningful QT prolongation or electrocardiogram abnormalities.
AB - Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert hematopathologists improves accuracy of subtyping, and referral to academic or specialty centers is recommended. Many patients, however, will receive treatment in the community, and knowledge of approved agents is key to optimizing therapeutic approaches for all patients. There is no current standard ofcare for patients with PTCL and no approved therapies for first-line treatment. Although many patients initially respond to induction chemotherapy, responses are often brief, and many patients relapse or become treatment refractory. For patients with relapsed or refractory PTCL, achievement of durable responses is challenging, and there are few treatment options. Romidepsin is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received one prior systemic therapy or more and patients with PTCL who have received one prior therapy or more. Approval of romidepsin for PTCL was based on a pivotal phase II study of patients with relapsed or refractory PTCL (n 5 131) that demonstrated an objective response rate of 25% including 15% with complete response; responses lasted a median of.2 years. Long-term responses to romidepsin were achieved in patients regardless of baseline characteristics, including subtype, heavy pretreatment, response to prior therapy, or advanced disease. Common adverse events included hematologic abnormalities, gastrointestinal or asthenic conditions, and infections; romidepsin was not correlated with clinically meaningful QT prolongation or electrocardiogram abnormalities.
KW - Lymphoma
KW - Peripheral
KW - Romidepsin
KW - T cell
UR - http://www.scopus.com/inward/record.url?scp=84940642439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940642439&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2015-0043
DO - 10.1634/theoncologist.2015-0043
M3 - Article
C2 - 26099743
AN - SCOPUS:84940642439
SN - 1083-7159
VL - 20
SP - 1084
EP - 1091
JO - Oncologist
JF - Oncologist
IS - 9
ER -